European Commission grants conditional marketing authorisation for Rozlytrek (entrectinib) for treatment of advanced solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion

Approval is based on results from pivotal phase 2/3 trials in which entrectinib, a selective tyrosine kinase inhibitor, produced durable responses across several NTRK gene fusion-positive solid tumours, including sarcoma, non-small cell lung, thyroid and more.